Pharmacokinetic and Pharmacodynamic Comparison of Immediate-Release and Sustained-Release Adinazolam Mesylate Tablets After Single- and Multiple-Dose Administration
- 1 January 1992
- journal article
- clinical trial
- Published by Springer Nature in Pharmaceutical Research
- Vol. 09 (4), 457-463
- https://doi.org/10.1023/a:1015875910222
Abstract
The effect of adinazolam release rate on psychomotor performance and sedation was assessed by administering 40 mg adinazolam mesylate immediate-release (CT) tablets, 60 mg sustained-release (SR) tablets, and placebo in a double-blind crossover study in 15 healthy male subjects. A separate panel of 16 subjects received the above single doses and multiple-dose regimens of 40 mg CT tablets every 8 hr and 60 mg SR tablets every 12 hr according to a crossover design. Psychomotor performance was assessed by digit symbol substitution test, card sorting tasks, and sedation ratings. Following single-dose administration, dose-corrected adinazolam and N-desmethyladinazolam (NDMAD) AUC values were equivalent for SR and CT tablets. Peak adinazolam and NDMAD levels were lower and occurred later for the SR tablets. Decrements in card sorting were 50 and 3% at 1 hr and 17 and 20% at 6 hr for the CT and SR tablets, respectively. Maximal sedation scores were lower for the SR tablets compared to the CT. Dose-corrected AUC was comparable between single and multiple doses for both adinazolam and NDMAD; no differences were observed in 24-hr AUC at steady-state between CT and SR tablets. Fluctuation ratios were reduced for both adinazolam and NDMAD following SR tablets. Psychomotor and sedative effects were attenuated upon multiple dosing. Thus, the reduction in peak plasma NDMAD following SR tablet administration results in a lesser sedation and psychomotor impairment on acute administration, and tolerance to these effects occurs on mulitiple dosing.Keywords
This publication has 14 references indexed in Scilit:
- Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate after single oral doses of each compound in healthy volunteersClinical Pharmacology & Therapeutics, 1990
- Pharmacokinetics and Pharmacodynamics of Alprazolam Following Single and Multiple Oral Doses of a Sustained-Release FormulationThe Journal of Clinical Pharmacology, 1989
- Double-Blind Comparison of Alprazolam and Adinazolam for Panic and Phobic DisordersJournal of Clinical Psychopharmacology, 1989
- Adinazolam pharmacokinetics and behavioral effects following administration of 20?60 mg oral doses of its mesylate salt in healthy volunteersPsychopharmacology, 1989
- Multiple-Dose Pharmacokinetics and Pharmacodynamics of Adinazolam in Elderly SubjectsPharmaceutical Research, 1989
- Pharmacodynamics of Triazolam After Intravenous AdministrationThe Journal of Clinical Pharmacology, 1987
- ADINAZOLAM - A NEW ANTIDEPRESSANT - FINDINGS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND-STUDY IN OUTPATIENTS WITH MAJOR DEPRESSION1987
- Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorderPsychopharmacology, 1986
- Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administrationPsychopharmacology, 1984
- Determination of biological activity of adinazolam and its metabolitesJournal of Pharmacy and Pharmacology, 1984